CMO Kirsten Gruis resigns; interim CMO Jordan Dubow appointed for stroke trial

DiaMedica Therapeutics Inc.

CMO Kirsten Gruis resigned effective Aug 31, 2023; she will consult for 9 months at $33,500/month.
Jordan Dubow, M.D., vascular neurologist with extensive CMO experience, engaged as interim CMO.
Dr. Dubow to accelerate site engagement and enrollment in Phase 2/3 ReMEDy2 trial of DM199 for acute ischemic stroke.
Dr. Dubow has served as CMO for eight companies and worked on 16 NDAs through FDA's Division of Neurology.
Separation agreement includes standard non-disparagement and confidentiality; no severance as resignation was voluntary.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kirsten Gruis

Chief Medical Officer

DMAC · DiaMedica Therapeutics Inc.

Effective: 2023-08-31
Successor: Jordan Dubow
Filed: September 5, 2023, 7:59 PM ET

On September 3, 2023, Kirsten Gruis, M.D. resigned from her position as Chief Medical Officer of DiaMedica Therapeutics Inc. (“DiaMedica” or the “Company”), effective as of August 31, 2023

Appointed (interim)

Jordan Dubow

Chief Medical Officer

DMAC · DiaMedica Therapeutics Inc.

Filed: September 5, 2023, 7:59 PM ET

To replace Dr. Gruis immediately on an interim basis while DiaMedica completes its search for a permanent Chief Medical Officer, DiaMedica has engaged as an independent consultant, Jordan Dubow, M.D.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kirsten Gruis resigned as Chief Medical Officer at DiaMedica Therapeutics Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On September 3, 2023, Kirsten Gruis, M.D. resigned from her position as Chief Medical Officer of DiaMedica Therapeutics Inc. (“DiaMedica” or the “Company”), effective as of August 31, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Jordan Dubow was appointed as Chief Medical Officer at DiaMedica Therapeutics Inc..

Action: engaged
Role: Chief Medical Officer

Exact text from the filing

To replace Dr. Gruis immediately on an interim basis while DiaMedica completes its search for a permanent Chief Medical Officer, DiaMedica has engaged as an independent consultant, Jordan Dubow, M.D.

View on SEC.gov

DiaMedica Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-025203

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.